Follow-up investigation of a cluster of treatment-naïve HIV-infected patients with multi-drug resistance in Sudbury, Ontario
|
|
- Lizbeth Anthony
- 5 years ago
- Views:
Transcription
1 Follow-up investigation of a cluster of treatment-naïve HIV-infected patients with multi-drug resistance in Sudbury, Ontario Ashleigh Sullivan, Penny Sutcliffe, Roger Sandre, P. Richard Harrigan, Chris Archibald, Jessica Halverson, Claudia Rank, James Brooks, Ann Burchell, Keyi Wu, Shannon Dowdall-Smith, Judy Latendre-Paquette, Robert S. Remis From: Public Health Ontario Public Health Agency of Canada Sudbury & District Health Unit HAVEN Program, Health Sciences North Dalla Lana School of Public Health, University of Toronto 22nd Annual Canadian HIV/AIDS Research Conference Vancouver, BC, April 11-14, 2013
2 Conflict of interest disclosure I have no conflicts of interest
3 Background: HIV drug resistance HIV drug resistance may reduce effectiveness of ART Need to monitor drug resistance to inform: Treatment options for individual patients Treatment guidelines Policy (e.g. treatment as prevention) Especially important to monitor drug resistance in treatment-naïve patients as an indicator of transmission of drug-resistant HIV strains
4 Background: Results of previous study Analyzed drug resistance in 2,118 HIV-positive patients in Ontario with genotyping prior to ART, 2005 to 2011 Overall, resistance by drug class was: NRTI 8.6%, NNRTI 5.6%, and PI 2.6%; 2.8% were multi-drug resistant (MDR) In Sudbury, Ontario, 53% were MDR, an unprecedented level of resistance
5 Sudbury HIV multi-drug resistance (MDR) Patients with MDR in Sudbury consistently had the following drug resistance mutations: NNRTI mutation K103N causes high level resistance to nevirapine and efavirenz NRTI mutations M41L and T215 revertant do not confer high level phenotype changes, but are significant and are one mutation away from M41L + T215Y, a combination which confers resistance to most NRTIs including: zidovudine, stavudine, didanosine, abacavir, and tenofovir
6 Study objectives Characterize the distribution of transmitted drug resistance among treatment-naïve patients in Sudbury Determine factors associated with MDR Examine access to care of persons diagnosed with HIV in Sudbury
7 Methods Case definition: Sudbury resident diagnosed with HIV from January 2005 to June 2012 Collected and reconciled data on: demographic characteristics, exposure category, race/ethnicity, and uptake of HIV care from: Public Health Ontario - HIV Laboratory HIV Laboratory Enhancement Program Sudbury & District Health Unit The HAVEN Program, Health Sciences North
8 Methods (continued) Sources of genotyping data: HIV genotyping prescribed on viral load specimens in the context of clinical care, BC Centre for Excellence Strain and Drug Resistance Program (SDR), Public Health Agency of Canada, on HIV diagnostic specimens Drug resistance results based on clinical genotyping results if available, and SDR otherwise Cases considered treatment-naïve if no ART and no prior undetectable viral load
9 Results: HIV cases 85 cases diagnosed in Sudbury Jan 2005 to Jun 2012 Majority (65%) male Average of 10.6 cases/year (range 3-19); no obvious trend over time Median age at diagnosis: 36 years (IQR 29, 44) Exposure category: IDU 63%, MSM 17%, MSM-IDU 7%, and other 14% Race/ethnicity: White 65%, Aboriginal 27%, and other 8%
10 Proportion treated at the HAVEN Program 89% attended the HAVEN Program at least once By sex: male 86%, female 97% By exposure category: IDU 94%, MSM-IDU 100%, MSM 79%, and other 75% By race/ethnicity: White 89%, Aboriginal 96%, and other 71% None of the above differences statistically significant
11 Attendance at the HAVEN Program (i.e. at least one visit) Proportion attended Overall 89% Sex Male 86% Female 97% Exposure category IDU 94% MSM-IDU 100% MSM 79% Other 75% Race/ ethnicity Aboriginal 96% White 89% Other 71% Differences were not statistically significant
12 HIV drug resistance by drug class 33% Drug resistance NRTI and NNRTI (MDR) 52% NRTI only NNRTI only No resistance 3% 12% Genotyping available for 78% (66/85) of cases; further analyses are restricted to cases which were genotyped
13 Multi-drug resistance by characteristics Tested MDR % MDR p value Sex Male % Female % Exposure category IDU % MSM-IDU % MSM % Other % <0.001 Race/ ethnicity Aboriginal % White % Other % Overall %
14 MDR rates by exposure category, sex, and race/ethnicity 100% IDU 100% Non-IDU Proportion resistant 80% 60% 40% 20% 0% Male Female Proportion resistant 80% 60% 40% 20% 0% Male Female 100% IDU 100% Non-IDU Proportion resistant 80% 60% 40% 20% 0% Aboriginal Non-Aboriginal Proportion resistant 80% 60% 40% 20% 0% Aboriginal Non-Aboriginal
15 Interpretation of MDR rates MDR rates much higher among IDUs, but also higher among women and Aboriginal persons However, there were more IDUs among women and Aboriginal persons Thus, the higher MDR rate among women and Aboriginal persons is likely entirely explained by the higher proportion of IDUs in these categories
16 MDR multivariate model Covariates Crude OR Adjusted OR P-value (adjusted) Age 0.97 ( ) 0.98 ( ) 0.56 Sex Male Female 3.5 ( ) 1.56 ( ) 0.52 Exposure category MSM & other IDU 44 ( ) 40 ( ) MSM-IDU 17 ( ) 22 ( ) Race/ethnicity Non-Aboriginal Aboriginal 2.1 ( ) 0.74 ( ) 0.66
17 Limitations 19 of 85 HIV-positive patients did not have a treatmentnaïve genotype People may have moved or sought care elsewhere Can assess drug resistance only in patients diagnosed Using genotyping data on specimens for clinical purposes may have introduced bias However, in Sudbury, patterns of drug resistance using HIV diagnostic specimens were the same as those from clinical genotyping
18 Conclusions HIV infection among IDU in Sudbury is an important public health problem Study confirms the need for routine HIV genotyping prior to treatment Aboriginal persons and women are over-represented in HIV cases and MDR, but related to injection drug use Access to care was, in general, excellent and did not vary significantly by patient characteristics High level of MDR HIV infection, especially among IDU, is of great potential concern
19 Future studies Examine clinical outcomes for patients in Sudbury with multi-drug resistance
20 Acknowledgements Stephanie Hastie, Gisele Sbrega, and support staff at Sudbury & District Health Unit Brenda Kirkbride at the HAVEN Program Health care workers who completed the Laboratory Enhancement Program (LEP) questionnaire Lisa Santangelo, Kevin McCurley for LEP data collection Public Health Agency of Canada for supporting this investigation and the Laboratory Enhancement Program AIDS Bureau, Ministry of Health and Long-Term Care for core support
21 Single-drug resistance (SDR) by characteristics Tested SDR % SDR p value Sex Male % Female % 0.74 Exposure category IDU % MSM-IDU % MSM % Other % 0.45 Race/ ethnicity Aboriginal % White % Other % 0.51 Overall %
Race/ethnicity of newly diagnosed HIV cases in Ontario,
Race/ethnicity of newly diagnosed HIV cases in Ontario, 2009-2011 Ashleigh Sullivan, Carol Swantee, Claudia Rank, Juan Liu, Robert W.H. Palmer, Mark Fisher, Keyi Wu, Robert S. Remis Public Health Ontario
More informationPatterns of HIV testing among Ontario physicians, 2006
Patterns of HIV testing among Ontario physicians, 2006 Claudia Rank, Robert S. Remis, Carol Swantee and Keyi Wu HIV Laboratory, Ontario Agency for Health Protection and Promotion Canadian Association of
More informationThe epidemiology of HIV infection among MSM in Ontario: The situation to 2009
The epidemiology of HIV infection among MSM in Ontario: The situation to 2009 Robert S. Remis, Juan Liu Ontario HIV Epidemiologic Monitoring Unit Dalla Lana School of Public Health University of Toronto
More informationEstimates of HIV Prevalence and Incidence in Canada, 2011
Estimates of HIV Prevalence and Incidence in Canada, 2011 Surveillance and Epidemiology Division Professional Guidelines and Public Health Practice Division Centre for Communicable Diseases and Infection
More informationRisk factors for first and subsequent syphilis diagnoses among HIV-positive gay and other men who have sex with men in Ontario Ann N.
Risk factors for first and subsequent syphilis diagnoses among HIV-positive gay and other men who have sex with men in Ontario Ann N. Burchell HIV and STIs November 19, 2013 3:20pm Ann N. Burchell, 1,
More informationMethodologic issues relating to the use of STARHS to determine HIV incidence: The Ontario experience
Methodologic issues relating to the use of STARHS to determine HIV incidence: The Ontario experience Robert S. Remis MD, MPH Department of Public Health Sciences, University of Toronto National HIV Prevention
More informationAntiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationHIV and AIDS among Aboriginal peoples in Canada: An Epidemiological Overview
HIV and AIDS among Aboriginal peoples in Canada: An Epidemiological Overview 2011 CAAN AGM Susanna Ogunnaike-Cooke, Jessica Halverson, Chris Archibald Surveillance and Risk Assessment Division Centre for
More informationHIV 1 Strain and Primary Drug Resistance in Canada
HIV 1 Strain and Primary Drug Resistance in Canada Surveillance Report to March 31, 2005 August 2006 This report is available: By mail Surveillance and Risk Assessment Division, Centre for Infectious Disease
More informationIncidence of chlamydia and gonorrhea co-infection among HIV-positive men who have sex with men in Ontario Ramandip Grewal
Incidence of chlamydia and gonorrhea co-infection among HIV-positive men who have sex with men in Ontario Ramandip Grewal HIV and STIs November 19, 2013 3:10pm Ramandip Grewal 1, Vanessa Allen 2, Sandra
More informationHIV care engagement among people with a history of injection drug use
HIV care engagement among people with a history of injection drug use Ann N. Burchell, PhD Scientist, Dept of Family and Community Medicine and Li Ka Shing Knowledge Institute St. Michael s Hospital burchella@smh.ca
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationThe HIV epidemic in Ontario: 2005 update
The HIV epidemic in Ontario: 2005 update Robert S. Remis MD, MPH, FRCPC Ontario HIV Epidemiologic Monitoring Unit Department of Provincial Community Planning Meeting AIDS Bureau, OMHLTC Toronto, Ontario,
More informationSocio-Demographic Factors associated with Success of Antiretroviral Treatment among HIV Patients in Tanzania
Socio-Demographic Factors associated with Success of Antiretroviral Treatment among HIV Patients in Tanzania Dr. Fausta Franklin Mosha (MD, MSc, MSc, PHD) Ministry of Health and Social Welfare 22 nd October
More informationThe epidemiology of hepatitis C infection in Ontario, 2004
The epidemiology of hepatitis C infection in Ontario, 2004 Robert S. Remis MD, MPH, FRCPC Department of Public Health Sciences University of Toronto Ontario Ontrario Harm Reduction Distribution Program
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationHIV Drug Resistance. Together, we can change the course of the HIV epidemic one woman at a time.
HIV Drug Resistance Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Resistance? HIV drugs are designed to keep the amount of HIV virus
More informationPatterns and predictors of dual contraceptive use among sexually active treatment experienced women living with HIV in British Columbia, Canada.
Patterns and predictors of dual contraceptive use among sexually active treatment experienced women living with HIV in British Columbia, Canada. Sophie Patterson 1,2, Wendy Zhang 1, Kate Salters 1, Yalin
More informationWomen with a history of injection drug use at greatest risk for poorer clinical outcomes in a cohort of HIV-positive individuals in Canada
Women with a history of injection drug use at greatest risk for poorer clinical outcomes in a cohort of HIV-positive individuals in Canada Angela Cescon, Alexis K Palmer, Keith Chan, Shari Margolese, Janet
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationTransmission Fitness of Drug- Resistant HIV Revealed in the United States National Surveillance System
Transmission Fitness of Drug- Resistant HIV Revealed in the United States National Surveillance System Joel O. Wertheim 1,2, Alexandra M. Oster 3, Jeffrey A. Johnson 3, William M. Switzer 3, Neeraja Saduvala
More informationThe epidemiology of injection drug use and bloodborne infection in Ontario
The epidemiology of injection drug use and bloodborne infection in Ontario Robert S. Remis, MD, MPH, FRCPC Ontario HIV Epidemiologic Monitoring Unit Department of HIV-IDU Frontline Workers Conference Toronto,
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationTransmitted antiretroviral drug resistance in a low HIV prevalence setting
University of Iowa Iowa Research Online Theses and Dissertations Summer 2012 Transmitted antiretroviral drug resistance in a low HIV prevalence setting Thuy Thi Vu Nguyen University of Iowa Copyright 2012
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More information2017 HIV/AIDS Epidemiology Update 2016 Data. James Dowling Health Program Coordinator Division of Public Health
2017 HIV/AIDS Epidemiology Update 2016 Data James Dowling Health Program Coordinator Division of Public Health Primary Sources Evaluation HIV/AIDS Reporting System (EHARS) Collects infection data from
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationImpact of HIV-1 Drug Resistance Testing on Clinical Outcome of Patients Receiving Highly Active Antiretroviral Therapy in Barbados
Impact of HIV-1 Drug Resistance Testing on Clinical Outcome of Patients Receiving Highly Active Antiretroviral Therapy in Barbados Songee Beckles, Ministry of Health NHAC Symposium December 3 rd 2012,
More informationGay Poz Sex (GPS): Qualitative findings of a Community-Based Counselling Intervention for HIV- Positive Gay and Bisexual Men
Gay Poz Sex (GPS): Qualitative findings of a Community-Based Counselling Intervention for HIV- Positive Gay and Bisexual Men Trevor A. Hart 1,2, Barry Adam 3,4, Natalie Stratton 1, John Maxwell 5, Robert
More informationUsing Partner Services Data to Enhance Molecular HIV Surveillance Cluster Analyses
Using Partner Services Data to Enhance Molecular HIV Surveillance Cluster Analyses Scott White, MS, MPH Epidemiology Manager Prevention, Treatment and Care Program Outline HIV in Utah Molecular HIV Surveillance
More informationSTOP HIV/AIDS Pilot Project
STOP HIV/AIDS Pilot Project QUARTERLY INDICATORS REPORT: 1 April through 30 June 2011 () SUBMITTED TO: The BC Ministry of Health Services SUBMITTED BY: Dr. Rolando Barrios, Dr. Mark Gilbert, Dr. Kate Health,
More informationGovernment of Canada Federal AIDS Initiative Milestones
HIV in Canada: Trends and Issues for Advancing Prevention, Care, Treatment and Support Through Knowledge Exchange Michael R Smith, Senior Policy Advisor, Programs and Coordination Division, Centre for
More informationA Genetic Test to Screen for Abacavir Hypersensitivity Reactions
The Future of Pharmacogenetics in HIV Clinical Care A Genetic Test to Screen for Abacavir Hypersensitivity Reactions Evan Collins & Misty Bath CANAC/ACIIS 15 th Annual Conference Vancouver, BC April 2007
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationTitle: What impact does missing Québec data have on national HIV surveillance data?
Track 1.2.4: Quantifying and Interpreting biases in epidemiologic and Title: What impact does missing Québec have on national HIV? Authors: Kristina Lalonde Tomas 1, Raphaël Bitera 2, Michel Alary 2, Micheline
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationReverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review
pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department
More informationNNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationBALTIMORE COUNTY HIV/AIDS EPIDEMIOLOGICAL PROFILE Fourth Quarter Data reported throuh December 31, 2007
Fourth Quarter 2007 - Data reported throuh AIDS Administration Maryland Department of Health and Mental Hygiene www.dhmh.state.md.us/aids/ 1-800-358-9001 SPECIAL NOTE ON HIV REPORTING The Maryland HIV/AIDS
More informationDifferences in Severity & Correlates of Depression between Men and Women Living with HIV in Ontario, Canada
Differences in Severity & Correlates of Depression between Men and Women Living with HIV in Ontario, Canada Kinda Aljassem, Janet M. Raboud, Anita Benoit, DeSheng Su, Shari L. Margolese, Sean B. Rourke,
More informationSummary: Estimates of HIV Prevalence and Incidence in Canada, 2011
Background Summary: Estimates of HIV Prevalence and Incidence in Canada, 2011 Surveillance and Epidemiology Division Professional Guidelines and Public Health Practice Division Centre for Communicable
More informationORIGINAL ARTICLE /j x. Brescia, Italy
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00938.x Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationUnderstanding contraceptive choices among a cohort of HIV-positive women
Understanding contraceptive choices among a cohort of HIV-positive women Malika Sharma, MD FRCPC with Blitz S, Walmsley S, Raboud J, Money D for the CTN 236 investigators January 13, 2014 Conflict of Interest
More information2018 HIV/AIDS Epidemiology Update 2017 Data. James Dowling Health Program Coordinator Division of Public Health
2018 HIV/AIDS Epidemiology Update 2017 Data James Dowling Health Program Coordinator Division of Public Health Primary Sources Evaluation HIV/AIDS Reporting System (EHARS) Collects infection data from
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More information3 rd International Workshop on Women and HIV Toronto, January 14 th, 2013
Anita C. Benoit 1, Lucia Light 2, Ann N Burchell 2, Sandra Gardner 2,3, Shari Margolese 1, Wangari Tharao 4, Gladys Kwaramba 5, Angela Kaida 6, Alexandra de Pokomandy 7, Bob Hogg 8, Mona Loutfy 1,4, CHIWOS
More informationGSS resistant intermediate resistant susceptible NRTI - NtRTI NNRTI etravirine PI PI/r EI INI dolutegravir
KU Leuven Rega Institute for Medical Research and University Hospitals Leuven Microbiology and Immunology Clinical and Epidemiological Virology Ricardo Camacho, 3, Kristel Van Laethem, 2, Anna Maria Geretti
More informationClinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy
8 The Open Virology Journal, 2007, 1, 8-13 Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy Harout K. Tossonian 1, Jesse D. Raffa 2, Jason Grebely
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationNON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION. Jason E. Vercher, PA-C, AAHIVM
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION Jason E. Vercher, PA-C, AAHIVM Disclosures No disclosures to report Learning Objectives q Identify Individuals who would benefit from non-occupational
More informationPerspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine
More informationAntiviral Therapy 2011; 16: (doi: /IMP1851)
Antiviral Therapy 2011; 16:925 929 (doi: 10.3851/IMP1851) Short communication Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationHIV Endgame II: Stopping the Syndemics that Drive HIV
Sean B. Rourke, Ph.D., FCAHS Scientific and Executive Director, OHTN Professor of Psychiatry, University of Toronto Director, CIHR Centre for REACH 2.0 in HIV/AIDS Director, CIHR Collaborative Centre for
More informationHIV/Hepatitis co-infection situation in Romania. Oana Săndulescu, MD, PhD
HIV/Hepatitis co-infection situation in Oana Săndulescu, MD, PhD Carol Davila University of Medicine and Pharmacy National Institute of Infectious Diseases Prof. Dr. Matei Balș Bucharest, Disclosures Carol
More informationSeparate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin
Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity Patrick Ingiliz, Berlin Back in the days when HCV genotype 1 was the problem SVR (%) 100 90 80 70 60 50 40 30 20 10 0 35% PRESCO
More informationTime-dependent bias related to Hepatitis C classification in a cohort of HIV-positive individuals
Time-dependent bias related to Hepatitis C classification in a cohort of HIV-positive individuals Jennifer Gillis, Curtis Cooper, Ann Burchell, Sandra Gardner, Michael Manno, Sean B. Rourke, Janet Raboud,
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationThe profile of people living with HIV
HIV AND AIDS IN SASKATCHEWAN, 212 ANNUAL REPORT RELEASE DATE: NOVEMBER 3, 213 Population Health Branch Purpose This report examines HIV and AIDS surveillance data reported in Saskatchewan to provide an
More informationComprehensive Epi Update: HIV, AIDS and STI Mark Gilbert, MD
Comprehensive Epi Update: HIV, AIDS and STI Mark Gilbert, MD February 2014 Objectives Recognize importance of disease syndemics To review current provincial trends: HIV AIDS Infectious syphilis Chlamydia
More informationMortality Slide Series. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention
Mortality Slide Series National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention HIV Mortality Slides An analysis of trends in rates and distributions of deaths
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationDescriptive Epidemiology of STBBIs in the Winnipeg Health Region
Descriptive Epidemiology of STBBIs in the Winnipeg Health Region Pierre Plourde Souradet Shaw Debbie Nowicki Mandy Whitlock March 22, 211 Methods Case definitions and case reporting In Manitoba, all confirmed
More informationState of Alabama HIV Surveillance 2014 Annual Report
State of Alabama HIV Surveillance 2014 Annual Report Prepared by: Division of STD Prevention and Control HIV Surveillance Branch Contact Person: Richard P. Rogers, MS, MPH richard.rogers@adph.state.al.us
More informationPatterns of Resistance to Antiretroviral Therapy among HIV+ Patients in Clinical Care
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 11-15-2006 Patterns of Resistance to Antiretroviral Therapy among
More informationHIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe
HIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe V Kouamou 1, J Manasa 1, D Katzenstein 1, A McGregor 1, CE Ndhlovu 1 & AT Makadzange 1. 1 University of Zimbabwe Introduction
More informationImproving accessibility to antiretroviral drugs: A south-south collaboration
Improving accessibility to antiretroviral drugs: A south-south collaboration Jaideep A Gogtay MD Cipla Ltd Mumbai jgogtay@cipla.com Adults and children estimated to be living with HIV at the end of 2000
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationDepression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention
The Alfred Hospital Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Final Report August 2005 Chief Investigator Associate Professor Anne Mijch Infectious Diseases
More informationManitoba Health Statistical Update on HIV/AIDS
Manitoba Health Statistical Update on HIV/AIDS 1985-2002 Communicable Disease Control Unit Public Health MANITOBA HEALTH STATISTICAL UPDATE ON HIV/AIDS 1985 TO December 2002 HIV January 1, 1985 to December
More informationBehind the Cascade: Analyzing Spatial Patterns Along the HIV Care Continuum
Behind the Cascade: Analyzing Spatial Patterns Along the HIV Care Continuum Kathleen Brady 1,2, M. Eberhart 1, A. Hillier 2, C. Voytek 2, M. Blank 2, I. Frank 2, D. Metzger, 2 B. Yehia 2 1 Philadelphia
More informationDr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.
BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationHIV-1 co-receptor tropism in recently diagnosed patients: correlates of CXCR4-use, impact of subtype and indications for X4/DM virus transmission
Poster nr. O_26 HIV-1 co-receptor tropism in recently diagnosed patients: correlates of CXCR4-use, impact of subtype and indications for X4/DM virus transmission Kristen Chalmet, Kenny Dauwe, Lander Foquet,
More informationSexual Health, HIV, and STDs
Sexual Health, HIV, and STDs Richard J. Wolitski, PhD Deputy Director, Behavioral and Social Science Division of HIV/AIDS Prevention Centers for Disease Control & Prevention Fenway Institute, Boston, MA
More informationHIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
More information3 rd International Workshop on Women and HIV January 14 th, 2013
3 rd International Workshop on Women and HIV January 14 th, 2013 Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on
More informationSTOP HIV/AIDS Pilot Project
STOP HIV/AIDS Pilot Project INDICATORS QUARTERLY REPORT: 1 October through 31 December SUBMITTED TO: The BC Ministry of Health Services SUBMITTED BY: Dr. Rolando Barrios, Dr. Mark Gilbert, Dr. Kate Health,
More informationTransmission of integrase resistance HIV
Transmission of integrase resistance HIV Charles Boucher, MD, PhD Clinical Virology, Dept. Viroscience, Erasmus Medical Center, Erasmus Universiy, The Netherlands Major resistance mutations (Stanford)
More informationEvaluation and Management of Virologic Failure
National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
More informationD:A:D Study Teaching Material
D:A:D Study Teaching Material Data Collection of Adverse events of anti-hiv Drugs (D:A:D) study December 2012 - CHIP Background The D:A:D Study, is a prospective cohort study (collaboration) initiated
More informationHIV & AIDS Cases in Alameda County
HIV & AIDS Cases in Alameda County Presentation to the CCPC August 24, 2011 Elaine Bautista & Alex Marr What is Epidemiology? The study of the distributions (who, where and when) and determinants (what
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationWhole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy
Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy K El Bouzidi 1,, RP Datir 1, V Kwaghe 3, S Roy 1, D Frampton
More information1. E-learning: NHIVNA HIV modules on the NHIVNA website
Vers Jan 18 E LEARNING sessions to complete for STIF NHIVNA Core Competency 1. E-learning: NHIVNA HIV modules on the NHIVNA website http://www.nhivna.org/nhivna-hiv-nursing-modules.aspx The NHIVNA HIV
More informationPersons Living with HIV/AIDS, San Mateo County Comparison
Persons Living with HIV/AIDS, San Mateo County Comparison As of December 2008, there were 1,152 persons living with HIV or HIV/AIDS in San Mateo County (Table 1). Compared to California and the United
More informationBHIVA Audit Survey of patient assessment and monitoring. starting ART from naïve. Survey of patient assessment and monitoring
BHIVA Audit 2006-7 Survey of patient assessment and monitoring Set-up phase of cohort audit of patients starting ART from naïve Survey of patient assessment and monitoring BHIVA s first online audit project,
More informationEnhanced HIV Partner Notification is Highly Effective at Diagnosing HIV in Vancouver, Canada
Enhanced HIV Partner Notification is Highly Effective at Diagnosing HIV in Vancouver, Canada Canadian Public Health Association Conference 2015 Logan Chinski, RN HIV Nurse Educator Vancouver Coastal Health
More informationDATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA.
Viral Load DNA >> Standard PCR standard 0 Copies Catalog Number: 1122 Lot Number: 150298 Release Category: A Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter
More informationHIV drug resistance and tracing outcomes among antiretroviral therapy defaulters in Malawi
HIV drug resistance and tracing outcomes among antiretroviral therapy defaulters in Malawi Bello G 1, ParkinN 2, KagoliM 1, ChipetaS 1, CzaickiN 3, Pry J 3, OdenyT 3, NyasuluI 4, LapointeH 5, Doherty M
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of Risk Management Plan for PREZISTA (Darunavir [TMC114]) This is a summary of the risk management plan (RMP) for PREZISTA. The RMP details important
More information